Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

aTyr Pharma

DB:471A
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
471A
DB
$27M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The last earnings update was 11 days ago. More info.


Add to Portfolio Compare Print
  • aTyr Pharma has significant price volatility in the past 3 months.
471A Share Price and Events
7 Day Returns
-20.4%
DB:471A
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-63.1%
DB:471A
-13.5%
DE Biotechs
-20.9%
DE Market
471A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
aTyr Pharma (471A) -20.4% -36.2% -59.3% -63.1% -94.6% -
DE Biotechs -0.7% -7.8% -21.1% -13.5% 12.9% -11.9%
DE Market -0.6% -16.6% -26% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 471A underperformed the Biotechs industry which returned -13.5% over the past year.
  • 471A underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
471A
Industry
5yr Volatility vs Market
Related Companies

471A Value

 Is aTyr Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for aTyr Pharma. This is due to cash flow or dividend data being unavailable. The share price is €2.26.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for aTyr Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are aTyr Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:471A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-7.03
NasdaqCM:LIFE Share Price ** NasdaqCM (2020-04-03) in USD $2.9
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of aTyr Pharma.

DB:471A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:LIFE Share Price ÷ EPS (both in USD)

= 2.9 ÷ -7.03

-0.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • aTyr Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • aTyr Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does aTyr Pharma's expected growth come at a high price?
Raw Data
DB:471A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-17.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for aTyr Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on aTyr Pharma's assets?
Raw Data
DB:471A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.44
NasdaqCM:LIFE Share Price * NasdaqCM (2020-04-03) in USD $2.9
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:471A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:LIFE Share Price ÷ Book Value per Share (both in USD)

= 2.9 ÷ 5.44

0.53x

* Primary Listing of aTyr Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • aTyr Pharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess aTyr Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. aTyr Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

471A Future Performance

 How is aTyr Pharma expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-17.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is aTyr Pharma expected to grow at an attractive rate?
  • Unable to compare aTyr Pharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare aTyr Pharma's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • aTyr Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:471A Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:471A Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -17.8%
DB:471A Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 39%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:471A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:471A Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 12 -52 -50 3
2023-12-31 0 -49 -66 3
2022-12-31 0 -43 -49 3
2021-12-31 0 -36 -39 3
2020-12-31 6 -20 -25 3
2020-04-06
DB:471A Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -20 -24
2019-09-30 0 -20 -24
2019-06-30 0 -22 -25
2019-03-31 -27 -30
2018-12-31 -31 -35
2018-09-30 -37 -40
2018-06-30 -39 -44
2018-03-31 -39 -45
2017-12-31 -42 -48
2017-09-30 -44 -49
2017-06-30 -50 -52
2017-03-31 -54 -55

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • aTyr Pharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • aTyr Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:471A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from aTyr Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:471A Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -2.70 -2.16 -3.24 2.00
2023-12-31 -3.96 -2.24 -5.67 2.00
2022-12-31 -3.06 -1.91 -4.20 2.00
2021-12-31 -2.86 -2.04 -3.68 2.00
2020-12-31 -2.52 -2.44 -2.60 2.00
2020-04-06
DB:471A Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -7.03
2019-09-30 -8.20
2019-06-30 -10.21
2019-03-31 -13.56
2018-12-31 -16.11
2018-09-30 -18.60
2018-06-30 -21.24
2018-03-31 -23.31
2017-12-31 -26.13
2017-09-30 -28.43
2017-06-30 -30.62
2017-03-31 -32.58

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if aTyr Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess aTyr Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
aTyr Pharma has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

471A Past Performance

  How has aTyr Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare aTyr Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • aTyr Pharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare aTyr Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare aTyr Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
aTyr Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from aTyr Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:471A Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.42 -23.60 9.35
2019-09-30 0.28 -23.95 9.25 20.39
2019-06-30 0.09 -25.42 9.84 20.39
2019-03-31 -29.99 10.90 17.58
2018-12-31 -34.52 12.44
2018-09-30 -39.67 15.91 5.31
2018-06-30 -43.74 17.13 12.44
2018-03-31 -45.47 17.14 27.01
2017-12-31 -48.21 17.08
2017-09-30 -49.30 14.57 33.90
2017-06-30 -51.93 14.35 37.16
2017-03-31 -55.17 14.99 40.05
2016-12-31 -57.86 15.09 42.85
2016-09-30 -61.78 15.52 46.37
2016-06-30 -59.29 15.63 43.72
2016-03-31 -55.00 14.90 39.91
2015-12-31 -47.99 13.11 33.10
2015-09-30 -37.53 10.99 24.78
2015-06-30 -32.97 9.24 21.45
2015-03-31 -27.61 7.56 17.58
2014-12-31 -24.77 6.78 16.78
2014-09-30 -24.30 6.29 16.55
2013-12-31 -21.65 5.71 13.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if aTyr Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if aTyr Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if aTyr Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess aTyr Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
aTyr Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

471A Health

 How is aTyr Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up aTyr Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • aTyr Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • aTyr Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of aTyr Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from aTyr Pharma Company Filings, last reported 3 months ago.

DB:471A Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 21.03 8.74 31.14
2019-09-30 26.74 10.59 38.06
2019-06-30 30.23 12.42 42.40
2019-03-31 29.49 14.23 43.02
2018-12-31 33.65 16.03 49.55
2018-09-30 38.99 17.81 55.96
2018-06-30 45.38 19.57 64.33
2018-03-31 54.50 19.98 74.10
2017-12-31 64.25 19.73 85.12
2017-09-30 72.29 14.75 90.38
2017-06-30 40.03 14.58 57.22
2017-03-31 50.71 9.57 61.93
2016-12-31 62.80 9.54 72.15
2016-09-30 73.99 2.64 70.53
2016-06-30 86.57 3.49 83.93
2016-03-31 100.43 4.32 86.05
2015-12-31 115.05 5.14 95.54
2015-09-30 129.16 5.95 108.80
2015-06-30 139.34 6.74 102.96
2015-03-31 43.29 9.51 54.51
2014-12-31 4.61 10.28 15.85
2014-09-30 9.63 11.03 23.45
2013-12-31 27.08 6.89 36.46
  • aTyr Pharma's level of debt (41.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (203.8% vs 41.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • aTyr Pharma has sufficient cash runway for 1.6 years based on current free cash flow.
  • aTyr Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.8% each year.
X
Financial health checks
We assess aTyr Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. aTyr Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

471A Dividends

 What is aTyr Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from aTyr Pharma dividends.
If you bought €2,000 of aTyr Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate aTyr Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate aTyr Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:471A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 315 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:471A Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as aTyr Pharma has not reported any payouts.
  • Unable to verify if aTyr Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of aTyr Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as aTyr Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess aTyr Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can aTyr Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. aTyr Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

471A Management

 What is the CEO of aTyr Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sanjay Shukla
COMPENSATION $568,336
AGE 47
TENURE AS CEO 2.4 years
CEO Bio

Dr. Sanjay S. Shukla, M.D., M.S., has been the Chief Executive Officer and President at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. from March 2016 to November 1, 2017. Dr. Shukla served as Vice President and Global Head of Integrated Medical Services for Novartis, he led global medical affairs operations, with oversight for all pharma general medicines therapies, both inline and in development. These included brands such as Gilenya, Cosentyx and Entresto. In addition, Dr. Shukla led the creation and development of the Real World Evidence Center for Excellence as well as incubating the Digital Strategy group within Global Medical Affairs. Previously, he served as Chief Executive Officer of RxMd, a clinical development consultancy that assisted in advancing proof of concept for early stage drug candidates. Prior to that, Dr. Shukla served in a variety of clinical development, data analytics and drug safety roles at Vifor Pharma and Aspreva Pharmaceuticals. He serves as a Member of Advisory Board at nPruv, Inc. and RxMD. Dr. Shukla received his M.D. from Howard University College of Medicine and his Bachelors of Science in Microbiology and Master of Science in Epidemiology and Biostatistics from the University of Maryland.

CEO Compensation
  • Sanjay's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Sanjay's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the aTyr Pharma management team in years:

2.3
Average Tenure
54
Average Age
  • The tenure for the aTyr Pharma management team is about average.
Management Team

Sanjay Shukla

TITLE
President
COMPENSATION
$568K
AGE
47
TENURE
2.4 yrs

Jill Broadfoot

TITLE
Chief Financial Officer
COMPENSATION
$395K
AGE
57
TENURE
1.8 yrs

Nancy E. Krueger

TITLE
General Counsel & Corporate Secretary
COMPENSATION
$399K
AGE
51
TENURE
5.5 yrs

Xiang-Lei Yang

TITLE

Peter Villiger

TITLE
Vice President of Corporate Development
TENURE
0.3 yrs

Ying Buechler

TITLE
Executive Director of Biologics Development & Manufacturing

Melissa Ashlock

TITLE
Senior Advisor
COMPENSATION
$1M
AGE
61
TENURE
8.9 yrs

David King

TITLE
Scientific Consultant
COMPENSATION
$717K
AGE
60
TENURE
1.3 yrs

Sanuj Ravindran

TITLE
Business Advisor
COMPENSATION
$1M
AGE
47
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the aTyr Pharma board of directors in years:

10.5
Average Tenure
71.5
Average Age
  • The average tenure for the aTyr Pharma board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

John Clarke

TITLE
Independent Chairman of the Board
COMPENSATION
$102K
AGE
65
TENURE
14.6 yrs

Sanjay Shukla

TITLE
President
COMPENSATION
$568K
AGE
47
TENURE
2.4 yrs

Jim Blair

TITLE
Independent Director
COMPENSATION
$60K
AGE
79
TENURE
9.3 yrs

Tim Coughlin

TITLE
Independent Director
COMPENSATION
$76K
AGE
52
TENURE
3 yrs

Paul Schimmel

TITLE
Independent Director
COMPENSATION
$46K
AGE
78
TENURE
14.6 yrs

Bruce Beutler

TITLE
Member of Scientific Advisory Board
TENURE
10.7 yrs

Osamu Nureki

TITLE
Member of Scientific Advisory Board
TENURE
10.6 yrs

Floyd Bloom

TITLE
Member of Scientific Advisory Board
AGE
82
TENURE
10.5 yrs

Ben Cravatt

TITLE
Member of Scientific Advisory Board

Susan Ackerman

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by aTyr Pharma individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
11. Feb 20 Buy Paul Schimmel Individual 10. Feb 20 10. Feb 20 254,000 €3.89 €989,038
X
Management checks
We assess aTyr Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. aTyr Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

471A News

Simply Wall St News

471A Company Info

Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for regulating immune engagement in interstitial lung diseases. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children’s Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was founded in 2005 and is headquartered in San Diego, California.

Details
Name: aTyr Pharma, Inc.
471A
Exchange: DB
Founded: 2005
$25,139,608
9,352,498
Website: http://www.atyrpharma.com
Address: aTyr Pharma, Inc.
3545 John Hopkins Court,
Suite 250,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM LIFE Common Shares Nasdaq Capital Market US USD 08. May 2015
DB 471A Common Shares Deutsche Boerse AG DE EUR 08. May 2015
Number of employees
Current staff
Staff numbers
42
aTyr Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 03:48
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.